Serum bicarbonate and cardiovascular events in hypertensive adults: results from the Systolic Blood Pressure Intervention Trial
Open Access
- 1 August 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 35 (8), 1377-1384
- https://doi.org/10.1093/ndt/gfz149
Abstract
Low serum bicarbonate level is associated with increased mortality, but its role as a predictor of cardiovascular disease (CVD) is unclear. This study evaluates the association between serum bicarbonate concentration and CVD and whether the effect of intensive blood pressure (BP) lowering on CVD outcomes is modified by serum bicarbonate level. The Systolic Blood Pressure Intervention Trial (SPRINT) randomized participants to a systolic BP target <120 mmHg (intensive treatment) or <140 mmHg (standard treatment). The primary CVD outcome was a composite of nonfatal myocardial infarction (MI), acute coronary syndrome not resulting in MI, stroke, acute decompensated heart failure and CVD death. Cox proportional hazards models adjusted for demographic, clinical and laboratory characteristics were used to evaluate the association of interest in 9334 SPRINT participants (ClinicalTrials.gov: NCT01206062). Over a median follow-up of 3.33 years (interquartile range 2.87–3.87 years), 618 (6.6%) participants experienced a primary CVD outcome. Participants with serum bicarbonate <22 mEq/L had a significantly higher risk of the primary CVD outcome (hazard ratio 1.54; 95% confidence interval 1.11–2.14, P = 0.01), compared with participants with bicarbonate 22–26 mEq/L. The magnitude of the CVD risk reduction with intensive BP lowering was similar across bicarbonate strata (P-value for interaction = 0.97). In hypertensive individuals, serum bicarbonate level <22 mEq/L was associated with an increased CVD risk. The effect of intensive BP lowering on CVD outcomes was not modified by the serum bicarbonate level.Funding Information
- National Institutes of Health
- NIH
- National Heart, Lung, and Blood Institute
- NHLBI
- National Institute of Diabetes and Digestive and Kidney Diseases
- NIDDK
- National Institute on Aging
- NIA
- National Institute of Neurological Disorders and Stroke
- NINDS (HHSN268200900040C, HHSN268200900046C, HHSN268200900047C, HHSN268200900048C, HHSN268200900049C, A-HL-13-002-001)
This publication has 33 references indexed in Scilit:
- Association of Serum Bicarbonate With Risk of Renal and Cardiovascular Outcomes in CKD: A Report From the Chronic Renal Insufficiency Cohort (CRIC) StudyAmerican Journal of Kidney Diseases, 2013
- Acidosis Activation of the Proton-Sensing GPR4 Receptor Stimulates Vascular Endothelial Cell Inflammatory Responses Revealed by Transcriptome AnalysisPLOS ONE, 2013
- Genetic Variation of ITGB3 Is Associated with Asthma in Chinese Han ChildrenPLOS ONE, 2013
- Mild metabolic acidosis impairs the β-adrenergic response in isolated human failing myocardiumCritical Care, 2012
- Activation of GPR4 by Acidosis Increases Endothelial Cell Adhesion through the cAMP/Epac PathwayPLOS ONE, 2011
- Serum Bicarbonate and Mortality in Stage 3 and Stage 4 Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2011
- Low-Level Laser Therapy Activates NF-kB via Generation of Reactive Oxygen Species in Mouse Embryonic FibroblastsPLOS ONE, 2011
- Consequences and therapy of the metabolic acidosis of chronic kidney diseasePediatric Nephrology, 2010
- Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKDNephrology Dialysis Transplantation, 2008
- Chemical and hormonal determinants of vascular calcification in vitroKidney International, 2006